ARCA biopharma (NASDAQ: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, recently reported financial results for the quarter ended March 31, 2018, as well as an update regarding its lead product candidate, Gencaro™. Among other highlights, the company reported ending the quarter with cash, cash equivalents and marketable securities of $12.1 million, compared to $11.8 million as of December 31, 2017. The company has scheduled an end-of-phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) for the last week of June to review data from the GENETIC-AF clinical trial and potential upcoming development plans. Additionally, the company’s Phase 2B GENETIC-AF clinical trial has been selected for a “Late Breaking Clinical Trials” oral presentation at the European Society of Cardiology Heart Failure 2018 World Congress taking place on May 27, 2018, in Vienna, Austria. “The first quarter of this year saw an important milestone for the Gencaro development program with the reporting of top-line Phase 2B results for the GENETIC-AF clinical trial evaluating Gencaro as potentially the first genetically-targeted treatment for atrial fibrillation,” ARCA biopharma president and CEO Dr. Michael Bristow stated in the news release.
About ARCA Biopharma
ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA’s lead product candidate, Gencaro™ (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of patients with atrial fibrillation (“AF”) and chronic heart failure with reduced left ventricular ejection fraction (“HFrEF”) which recently completed a Phase 2B clinical trial. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted AF prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. The Gencaro development program has been granted Fast Track designation by FDA. ARCA also plans to develop AB171, a thiol-substituted isosorbide mononitrate, as a potential genetically-targeted treatment for peripheral arterial disease (“PAD”) and for heart failure (“HF”). For more information, visit the company’s website at www.arcabio.com.
More from NetworkNewsBreaks
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com